Ticlopidine is a platelet aggregation inhibitor used in the prevention of conditions associated with thrombi, such as stroke and transient ischemic attacks (TIA). It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation.
- Mechanism
- Curator reviewed
The active metabolite of ticlopidine prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. No direct interference occurs with the GPIIb/IIIa receptor. As the glycoprotein GPIIb/IIIa complex is the major receptor for fibrinogen, its impaired activation prevents fibrinogen binding to platelets and inhibits platelet aggregation. By blocking the amplification of platelet activation by released ADP, platelet aggregation induced by agonists other than ADP is also inhibited by the active metabolite of ticlopidine.
- Primary indication
- Used in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.Curator reviewed · 5 structured indications
- Formula / weight
- C14H14ClNS · 263.786 g/mol (avg)
- First approval
- Canada, 1997 · United States, 1991
Resolves to
PHWBOXQYWZNQIN-UHFFFAOYSA-NSMILESClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2What you can answer from here — as of September 23, 2026
Which drugs share a target with Ticlopidine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account